Preclinical evidence reported synergistic anti-tumor effects with anti-CD73 and PD-1/PD-L1 antibodies, due to a greater increase in intra-tumoral infiltration of CD8+ T cells [188,189]. This evidence concerns the gene NT5E and neoplasm.